Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Prekallikrein-directed antisense oligonucleotides
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Prekallikrein-directed antisense oligonucleotides

1 evidence topic · 1 source

Donidalorsen: prophylaxis and dosing interval

“DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE)” (opens the source at this quote in a new tab)
“every four or eight weeks.” (opens the source at this quote in a new tab)